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ABSTRACT 
Background and objectives: 
 Cardiovascular disease(CVD) is the leading cause of morbidity and 
mortality in patients with Chronic kidney disease(CKD). The mortality due to 
cardiovascular disease is 15-30 times higher in dialysis patients. Our aim is to 
study Electrocardiographic changes in patients with CKD. 
Materials and methods: 
 75 consecutive patients of CKD admitted in thanjavur medical college 
hospital were taken up for the study.  Patients were evaluated with history, 
general examination, systemic examination, Blood investigations, ECG, etc., 
Results: 
In our study changes in ECG among CKD patients constituted to around 71% of 
the study population. The commonest ECG finding was Left ventricular 
hypertrophy constituting to 29% of study population. Ischemic changes in ECG 
were found to be in 23%, Conduction disturbances were found to be in 17%, 
Left atrial enlargement in ECG was found in 12%, Hyperkalemic ECG changes 
were found in 12% of our study population. The overall changes in ECG 
significantly (p value <0.05) correlated with the increasing age & presence of 
dyslipidaemia. The ischemic changes in ECG correlated significantly (p 
value<0.05) with the low HDL and high Triglyceride levels.  
Conclusion 
 CVD poses a major threat to patients with CKD. In the context of CKD 
aim of evaluating CVD is warranted. The changes in ECG of patients with CKD 
can aid in detection of CVD and should be carried out in all patients with CKD. 
Key words 
 Chronic kidney disease (CKD), Cardiovascular disease (CVD), 
Electrocardiography (ECG). 
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1. INTRODUCTION 
The epidemicity of chronic kidney disease, full spectrum of which ranges from 
asymptomatic state to obvious kidney failure is being increasingly noted. 
Kidney failure being the most visible aspect of this spectrum, it represents only 
a minimal of total population affected by kidney disease [1]. 
Cardiovascular disease (CVD) is the leading cause of morbidity and 
mortality in patients with CKD. This risk of cardiovascular disease may begin in 
early stages of CKD much before the onset of kidney failure. This high burden 
of CVD mortality is well illustrated by comparing CVD mortality in dialysis 
population to general population. The mortality due to Cardiovascular disease is 
15-30 times higher in dialysis patients [1,2,3]. National Kidney Foundation 
(NKF) in their clinical guideline for CVD in dialysis patients recommended 
baseline electrocardiogram and echocardiograph at the onset of dialysis and at 
annual interval. 
The clinical manifestation of CKD and CVD overlap substantially and often 
missed on clinical examination, hence these abnormalities has to be evaluated 
by noninvasive, easily available diagnostic method to prevent morbidity and 
mortality.  
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 Even in this modern era of sophisticated investigations the use of cost effective 
non invasive modalities of investigations hold good for many disorders. One 
such investigation being electrocardiography for cardiovascular diseases. It is a 
very widely available investigation that can aid in the detection of ischemia to 
myocardium, conduction abnormalities of the heart, chamber enlargements & 
can even provide clues regarding the electrolyte abnormalities. The importance 
of this inevitable investigatory modality should be never neglected.  
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2. OBJECTIVE OF THE STUDY 
To study Electrocardiographic changes in patients with chronic kidney disease 
and to determine whether there is a correlation between the 
Electrocardiographic changes and duration of illness, stage of the illness or to 
any other potential factors.  
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3. REVIEW OF LITRETURE 
Atrophied Kidney a fatal consequence of chronic renal inflammation seen 
in early inhabitant of Nile valley was noticed by Dawson, Buffex and Smith. 
Charaka explained different urinary affection in 2nd century. Hipppocrates has 
given the detailed description of renal disease. He diagnosed certain affection of 
kidney by urinary examination. Soliceto, the Italian surgeon pointed out the 
association of dropsy, scanty urine and hardened kidneys. 
The term “Uremia” originally used to imply retention of urine in the blood by 
the Piorry and Lheritter. Jacobe Henly showed urinary casts under microscope. 
Fredrick Akabar Mohammed found relation between hypertension and renal 
disease. Herman and Straus described blood urea estimation in kidney disease. 
Fredrich Wholer synthesized the urea in laboratory. 
PHYSIOLOGY OF KIDNEYS 
The kidneys are paired organs in the shape of been seeds placed 
bilaterally and are located in the retroperitoneal space one on each side of the 
vertebral column. Each kidney weighs hundred and fifty grams and is about 
eleven cm length, six cm in width and three cm in thickness. Kidneys have a 
cortex which constitutes the outer segment and a medulla which constitutes the 
inner segment. The medullary portion of kidney has approximately 12 pyramids. 
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Each of the pyramid and the cortex overlying it together forms the renal lobe. 
The pyramids have two zones. 1)INNER ZONE also known as papilla & 
2)OUTER ZONE. This inner zone drains into the calyces which then drain into 
the renal pelvis. Renal pelvis further empties into the ureter. 
BLOOD VESSELS 
Kidneys receive around 20 to 25% of the cardiac output. This blood 
supply is derived from the branches of abdominal aorta, the renal arteries 
through its anterior and posterior branches.  After a series of successive 
divisions the afferent arterioles arise, each arteriole provides blood supply to a 
glomerulus. 
Capillaries are formed by the branching of efferent arteriole which drains the 
glomeruli. These capillaries either form the vasa recta or provide blood supply 
to the renal cortex. 
 Functional unit of the kidneys is known as the nephrons. It is composed of  
 The glomeruli 
 The tubules & 
 Collecting system 
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GLOMERULI  
 
Figure depicting the glomerulus 
 The glomeruli consist of capillary network which is covered by the epithelial 
cells and interspersed with mesangial cells. The afferent arteriole after entering 
the glomeruli divides into capillaries, forming a tuft and then converges into the 
efferent arteriole leaving the glomeruli. Capillary endothelium lies on basement 
membrane. On its other surface the membrane is covered by podocytes. The 
7 
 
Bowman space is the space between podocytes and the epithelium of the 
malphigian capsule. 
THE GBM  
The Glomerular Basement Membrane varies from other basement membranes in 
its composition and function. It is around 350 nm in thickness and has 3 
laminae.1)Lamina densa 2)Laminarara interna3)Laminarara externa. The GBM 
contains glycosaminoglycans abundant in heparin sulfate, which provides a 
negative charge to the GBM. The negative charge of the GBM facilitates 
filtration of neutral and positive charged molecules and relative exclusion of 
substances like albumin which are negatively charged. 
GLOMERULAR ENDOTHELIUM 
The Glomerular endothelium is 50 nm in thickness has pores in 60-100nm size. 
Membrane proteins in the endothelium, prostaglandins and nitric Oxide 
produced by the endothelium have a major role in much glomerular pathology. 
PODOCYTES 
Podocytes rest on the Glomerular basement membrane. Over the externa layer 
of  the GBM(Glomerular basement membrane)  the podocytes extend processes 
similar to that of feet which gives them the name foot process. The slit 
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diaphragm separates these projections. These podocytes provide a defense 
against proteinuria. Mutations in the various components of podocytes result in 
proteinuria and nephrotic syndrome. 
MESANGIUM 
 Mesangial cells are basically specialized smooth muscle cells that occupy the 
central area of glomeruli interspersed with the capillaries. Some of the function 
of mesangium: 
■ Endocytosis of immune complexes and many other proteins  
■Production of prostaglandins & cytokines. 
■acting as a matrix for glomerulus thus provides support. 
■Contractility of mesangial cells Modulates GFR. 
 TUBULES  
They are the  
 Proximal convoluted tubule  
 Distal convoluted tubule and 
 Loop of Henle.  
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The proximal convoluted tubule lined by tall columnar cells with microvilli 
forming the so called brush border. The proximal convoluted tubule then 
straightens into the thick descending limb of the loop of Henle. This thick limb 
thins to form the thin limb of the loop of Henle .the thin limb then becomes the 
thick ascending limb. Here it lies close to the glomeruli forming the ‘ juxta 
glomerular apparatus ’, Then the distal tubule arises from the thin ascending 
limb. Collecting duct is formed by the union of many distal tubules. ‘ Duct of  
Bellini ’ is formed by the union of collecting ducts . These ducts drain into the 
calyx via the papilla. 
THE JUXTAGLOMERULAR APPARATUS (JGA) 
The JGA consists of: 
■Macula densa 
■Extraglomerular mesangial cells 
■Terminal portion of the afferent arteriole and proximal portion of the efferent 
arteriole. 
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This JGA is responsible for the production and release of rennin and 
angiotensin. 
THE INTERSTITIUM 
The renal interstitial cell not only provides structural support, but also has some 
secretory function as of its cortical cells produce erythropoietin and medullary 
cell produce prostaglandins. 
FUNCTIONS OF KIDNEY 
The kidneys are the major organs in maintaining the homeostasis of the body by 
controlling excretion of various substances.  Few of the functions of kidneys are 
as follows 
 They increase the excretion of ions when their levels reach a higher level 
beyond a threshold. They Conserve ions by increasing the re absorption when 
they are in lower levels than normal. Thus they control the ionic concentration 
of body. Ions regulated by kidneys include sodium, potassium, phosphate, 
magnesium , calcium & chloride.   
 The kidneys conserve bicarbonate ions, the important blood pH buffer. They 
also excrete the hydrogen ions in excess. Thereby monitoring and regulation of 
hydrogen ion levels and bicarbonate ion levels, regulates the pH of the blood.  
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 Kidneys maintain osmolality of the blood by regulating the quantity of water 
excreted through the urine. When water is consumed in larger quantities, there is 
reduction in the reabsorption of water facilitating the excretion of excess water, 
producing a diluted urine .By the process of reabsorption, highly concentrated 
urine can be formed in response to dehydration. These changes are controlled by 
the anti-diuretic hormone. 
 Kidneys regulate the blood pressure. When blood pressure is high, kidneys by 
decreasing the blood volume normalizes the blood pressure. Conversely during 
times of hypotension, the kidneys secrete renin and there’s activation of the 
renin-angiotensin system to cause constriction of blood vessels and produce 
concentrated urine, thereby allowing the plasma volume to expand.  
 Kidneys produces Calcitriol, the active form of vitamin D. Calcitriol along with 
parathormone regulates the level of calcium ions in the blood. During times of 
hypocalcaemia parathormone is released from, the parathyroid glands. The 
parathormone stimulates the kidneys to produce calcitriol. This vitamin D3 
promotes the gut to absorb calcium avidly. There’s stimulation of osteoclasts 
causing the release of calcium ions in bloodstream. 
 Production of the Erythropoietin (EPO), the erythropoietic hormone. The kidney 
monitors oxygen-carrying capacity of the blood passing through its capillaries. 
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During times of hypoxia  the peritubular fibroblasts produce erythropoietin & 
releases into the blood. Erythropoietin stimulates hematopoietic cells in the 
marrow to increase production of RBCs, thus tries to improve the hemoglobin 
concentration so as to correct hypoxia.  
 Kidneys produce the renin to favor the activation of the renin-angiotensin 
system (RAS). The renin-angiotensin system during periods of hypotension, 
blood loss or dehydration expands the blood volume and increases the blood 
pressure. Renin converts the angiotensinogen produced in the liver to form 
angiotensin I. Angiotensin I is converted by angiotensin converting enzyme to 
form the Angiotensin II.  
 Angiotensin II is involved in varied mechanisms, one of them being the 
secretion of aldosterone by stimulation of adrenal cortex. Aldosterone in turn 
increases blood volume and increases the blood pressure by increasing the 
sodium and water reabsorption by the kidneys. There is a negative feedback 
mechanism based on this system to regulate levels of blood pressure. 
CHRONIC KIDNEY DISEASE 
Definition: Kidney damage for ≥3 months, defined as functional or structural 
Renal abnormality, along with or without reduced GFR, irrespective of the 
cause, manifest by either: 
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1.  Abnormal pathology;  
2. Markers of renal damage that includes abnormal composition of the blood or 
urine, or abnormal imaging studies. 
3. GFR less than 60 ml/min/1.73 m2 for ≥3 months, along with or without renal 
damage. 
Staging of CKD based on  GFR
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Risk Factors for Chronic Kidney Disease 
Established risk factors 
Age 
Gender (male predilection) 
Race (African American, Hispanic, Native American) 
High blood pressure 
Diabetes mellitus 
Obesity 
Metabolic syndrome 
Proteinuria 
Family history of kidney disease 
Smoking 
Atherosclerosis 
Exposure to nephrotoxins such as analgesics, heavy metals 
Dyslipidemia 
Reduced nephron number at birth 
Recurrent urinary tract infection 
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Emerging risk factors 
Oxidative stress 
Elevated plasma homocysteine level 
Anemia 
Prothrombotic factors (e.g., plasminogen inhibitor activator-1). 
 
PREVELANCE:  
The Third National Health and Nutrition Examination Survey (NHANESIII) 
showed the following observations related to CKD.  
•  6.2 million people had  serum creatinine  ≥ 1.5 mg/dL, showing that there is  
30-fold increased prevalence of reduced kidney function  when compared with 
that of  the  treated ESRD during the same time period.  
• 2.5 million people were  having serum creatinine  ≥  1.7 mg/dL.  
• 800,000 people had a serum creatinine ≥ 2.0 mg per dL.  
•   70% of the people with elevated serum creatinine levels had hypertension.  
•  Only three fourth of patients received  treatment despite having both 
hypertension and elevated serum creatinine levels, with only 27% having 
16 
 
 Reduced their blood pressure lower than 140/90 mm Hg and 11% having their 
BP reduced to lower than 130/85 mm Hg [4]. 
Estimation of Glomerular Filtration Rate: 
GFR is the preferred method for assessing kidney function and staging CKD for 
the purpose of diagnosis, prognosis, and management. There are several 
methods for measuring and estimating GFR. Each method has particular 
strengths, weaknesses, and limitations. Inulin clearance remains the gold 
standard. For clinical purposes, creatinine and cysC are good markers for 
measuring GFR [5]. For clinical management, serum creatinine-based estimates 
of GFR, including the Cockcroft Gault and MDRD equations, are the preferred 
methods. For research purposes, inulin and iothalamate clearances are accurate, 
reliable, and reproducible measures of GFR. 
Cockcroft – Gault Equation 
 
 The above equation calculates the creatinine clearance. It must be multiplied by 
the factor 0.85 in case of females. It is done because this formula’s assumption 
that when compared with males, females will have a low creatinine clearance by 
fifteen percentage. 
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Modification of Diet in Renal Disease Equation. 
 
Etiology of CKD. 
Renal Disease            Total % 
Diabetes mellitus         43.9 
Hypertension               26.2 
Glomerulonephritis       9.1 
Interstitial nephritis/pyelonephritis        3.8 
Cystic/hereditary/congenital diseases    3.2 
Secondary glomerulonephritis/vasculitis  2.2 
Neoplasms/tumors     1.9 
Miscellaneous      4.1 
Unknown       5.7 
Total         100 
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CAUSES OF CKD 
 
 
PATHOPHYSIOLOGY OF CKD: 
The kidneys amounts to 1% of total body weight, but the blood flow to kidneys 
constitutes to 20% of the total cardiac output, which is required for 
ultrafiltration. The volume of urine excreted represents the total of  two  
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opposite  physiological process namely, ultrafiltration of 180L/24hrs or more of 
plasma water and reabsorption by transport process in the renal tubules by 
which 99% of the above said filtrate is reabsorbed[6]. 
The pathophysiological of chronic renal failure involves two varied type of 
etiologies: 
• Initiating mechanisms which are brought about by varied causes e.g., in 
various types of glomerulonephritis via the immune complexes and various 
inflammatory mediators, or toxin exposure in certain cases of interstitial and 
tubular diseases of the kidney and 
• A set of progressive mechanisms, causing nephronal hypertrophy and hyper 
filtration, which are caused by over a longer durational decrease in the renal 
mass. 
Vasoactive hormones, cytokines, and growth factors mediate the response to 
reduction of renal mass and number of nephrons. 
As time progresses, the short lived compensations of nephronal 
hypertrophy and hyper filtration turns out in vain  as the increase in the 
glomerular pressure and increased flowing leads  to sclerosis and the remaining  
nephrons then get damaged. The initial part of short lived compensations of 
nephronal hypertrophy and hyper filtration is brought about by the raise in the 
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activity of renin –angiotensin system (RAS) within the kidney. Following this in 
the transforming growth factor (TGF-β) stimulation carries out the same 
activities during later stages. For these reasons there may be renal mass 
reduction following a single episode of insult to the kidney and may cause a 
continuous reduction in the function of the kidneys even over the decades [6]. 
In chronic kidney disease, compensatory and adaptive mechanisms 
maintain acceptable health until the GFR is about 10-15ml/min and life 
sustaining the renal excretory and homeostatic function continue until the 
glomerular filtration rate is less than 5ml/hr [7]. 
The metabolic product of protein and amino acids depends primarily on 
the kidneys for excretion unlike fats and carbohydrates, which are eventually 
metabolized to Co2 and water substance, which are readily excreted even in 
uremic subjects via lungs and skin. 
The pathophysiology of the uremic syndrome is divided into those sets of 
abnormalities consequent to the accumulation of end products of protein 
metabolism and the abnormalities consequent to the loss of fluid and electrolyte 
homeostasis and synthesis of certain hormones{e.g.:- erythropoietin EPO, 1.25-
dihydroxycholecalciferol}. 
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The kidney normally catabolizes a number of circulating plasma proteins 
and polypeptide which is reduced in renal failure. Furthermore, plasma levels of 
parathyroid hormone {PTH}, Insulin, Glucagon, Luteinizing hormone and 
prolactin hormone rise with renal failure-not only because of renal catabolism  
but also because of enhanced glandular secretion. PTH is an important toxin 
because of its adverse effect of elevating cellular cytosolic Ca2+ levels in 
several tissue and organs [8]. 
CLINICAL AND BIOCHEMICAL MANIFESTATION OF CKD. 
The symptoms of uraemia may develop insidiously and late. The most 
common and dominant symptoms are fatigue, dyspnoea, ankle swelling, 
Anorexia, vomiting, pruritus and inability to concentrate. Physically sign in 
chronic kidney disease depends on its degree of chronicity and its likely 
complication. Signs of chronicity include pallor, yellow brown skin 
discoloration and nail dystrophy.  
Other manifestation of chronic kidney disease includes hypertension, 
cardiomegaly, congestive cardiac failure and pericarditis. The florid 
manifestation of uraemia has largely disappeared because of chronic dialysis, 
which reduces the incidence and severity of disturbance in the function of every 
organ system secondary to uraemia[ 9]. 
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Anaemia 
Anaemia is common in CKD stages III through IV and Is due to the apparent 
deficiency of the hormone erythropoietin (EPO), and also  iron deficiency,  
reduced RBC life span ,vitamin deficiency of  folate or cyanocobalamine ,  and 
chronic inflammation  are frequent contributors. Anaemia may contribute to 
cardiac dysfunction by increasing cardiac output and there by exacerbate left 
ventricular hypertrophy [10].  
Although reversal of anaemia with erythropoietin has can cause the left  
ventricular hypertrophy to regress, there is currently no evidence that treatment 
is associated with an improved longer term cardiac prognosis, although its use 
may be associated with better quality of life. Debate remains as to the optimal 
target range of haemoglobin concentrations, with most guidelines 
recommending a level of 11 to 13 g/dl. Partial correction of anaemia does not 
accelerate the decline of renal function but may necessitate increases in 
antihypertensive therapy [10]. 
Water homeostasis 
Inability to concentrate urine is often the first symptom of CKD, resulting 
in polyuria, nocturia and thirst, when glomerular filtration rate is about is 
30ml/min or less. Diseases such as pyelonephritis, interstitial nephritis and 
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medullary cystic disease, which show their predominant effect on the medulla, 
may present with concentration defect at an earlier stage of CKD. This is due to 
increased solute load in serving nephrons. As obligatory water loss is increased 
there is need for careful attention to fluid balance in the presence of anorexia, 
fever, surgery and other sources of extra renal loss that leads to dehydration and 
hypertension [11]. 
Sodium homeostasis 
As the renal function decreases sodium balance and extracellular fluid 
volume are maintained until GFR is less than 10ml/min. The extent of this 
adaption such that 1% or less of filtered sodium excreted by normal subject 
increases to 30% in late CKD. In most patients with stable CKD the total body 
contents of Na+ and H2o are increased modestly, but may not be clinically 
evident. The major consequence of sodium and fluid excess is hypertension, 
present in 80% of patient in late CKD [11]. 
Potassium homeostasis 
Hyperkalemia may develop in CKD stages 4 and 5 and can be managed 
by dietary restriction to less than 60mg potassium daily. Patients with CKD may 
tolerate higher levels of potassium, and may not show change in ECG or may 
not develop arrythmia than those with acute kidney injury (AKI), but this is not 
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a consistent feature, and hyperkalemia should always be actively managed. 
Acute reductions in serum potassium are best achieved by glucose and insulin 
infusion; sodium bicarbonate is less effective in the setting of impaired renal 
function. Oral Resins (such as Kayexalate with sorbitol) are widely used in 
some countries but May cause gastrointestinal upset and can raise blood 
pressure because of sodium retention. Dialysis may be required acutely if the 
serum potassium concentration is markedly elevated (levels > 6.5 mmol/l). For 
chronic management of hyperkalemia, dietary potassium restriction and loop 
diuretics may be required. Haemodialysis patients with hyperkalemia may not 
exhibit the usual ECG changes possibly due to fluctuation in serum calcium 
[11]. 
Acid base balance 
The metabolic acidosis associated with CKD is caused by failure of 
hydrogen ion excretion and may be compounded by bicarbonate loss, 
particularly in interstitial kidney diseases and the accumulation of organic acids. 
Clinical symptoms from acidosis are rare until patients reach CKD stage 5, 
when dyspnea may occur. 
Acidosis causes increase in the serum level of potassium, decreases 
production of protein, and tends to increase the rate of resorption of calcium 
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from bones as the ionic hydrogen is being buffered in the bones. There is also 
emerging evidence that correction of metabolic acidosis slows progression of 
renal disease. Severe metabolic acidosis (e.g., serum bicarbonate < 20 mmol/l) 
associated with symptoms in a patient with CKD stage 5 is an indication to start 
dialysis. If dialysis is not immediately available, oral sodium bicarbonate in a 
dose up to 1.2 g four times daily may be considered, but sodium loading may 
aggravate hypertension [11]. 
Bone, Phosphates, Calcium abnormalities 
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Two principle types of bone disease observed in patient with ESRD:- 
1. High turnover-osteodystrophy {osteitis fibrosa cystica} 
2. Low turnover- osteodystrophy characterized initially by osteomalacia and 
subsequently by dynamic bone disease [12]. 
The High turnover-osteodystrophy is associated with elevated parathyroid 
hormone. The main factor responsible for deranged PTH synthesis in CKD is 
related to 
1. Altered Vitamin D metabolism and resistance to calcitriol 
2. Hypocalcemia 
3. Hyperphosphatemia 
4. Altered degradation of PTH hormone by the kidney 
Low-turnover bone disease can be grouped into two categories 
• Adynamic bone disease: 
Adynamic bone disease is increasing in prevalence, especially among diabetics 
and elderly. It manifests as a decrease in mineralization and volume of the bone 
and may result from excessive suppression of PTH production. Its complication 
can lead to pathological fractures and may lead to calcifications in the heart as 
well as blood vessels  
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• Osteomalacia: 
The bone matrix which gets deposited is largely unmineralised  which is 
brought about by  Reduced levels of vitamin D ,Increased accumulation of 
aluminium  or even metabolic acidosis.  
Cardiovascular morbidity and mortality increases proportionally with the 
increased levels of phosphate. This mechanism is effected not only in end stage 
diseases but also in patients with lower stages of chronic renal failure. There is 
excess calcification of blood vessels in proportion to increased levels of calcium 
and phosphate but there is uncertainty concerning the causation of excessive 
mortality by this mechanism. There can also be calcification in the valves of the 
heart. The level of calcification increases with advancing age. The possible 
mechanism of this excessive calcification is 
 1) Deposition of calcium in sites other than bone because of the defective 
mineralization of bone  
2) There is change in the genetic expression that causes the vascular 
endothelium to react as osteoblast like mechanism. The later mechanism is 
brought about by the hyperphosphatemia. 
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 CARDIOVASCULAR COMPLICATION OF CHRONIC KIDNEY 
DISEASE: 
Cardiovascular diseases is the most important and largely the  cause of death in 
chronic kidney disease largely due to the increase in the number of patients with 
end stage renal disease  and a wide  variety of factors which affect the functions 
of the heart. This increased risk of cardiovascular disease may begin even 
before the onset of renal failure in the beginning stages of chronic kidney 
disease. Patients with chronic kidney disease will have largely the traditional 
risk factors of CVD together with the presence of certain nontraditional risk 
factors that causes the increased burden of CVD. 
Cardiovascular disease is the important and largely the cause of death, 
accounting for nearly 45% of deaths; approximately 20% of cardiac deaths are 
attributed directly to acute myocardial infarction. At all ages in both men and 
women, deaths  due to CVD is 10 to 30 fold increased  in patients with CKD 
dependent on dialysis comparing to general population[13]. 
The anatomic and hemodynamic alteration of cardiovascular system in CKD is 
• Increased total body and vascular volume. 
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• Increased blood pressure. 
• Left ventricular hypertrophy. 
• Increased pulmonary capillary permeability. 
• Increased cardiac index. 
• Increased left ventricular chamber size. 
• Increased serosal membrane permeability. 
• Increased total peripheral resistance [14]. 
• Impaired left ventricular contractile function {decreased ejection fraction}. 
Cardiac risk factors in chronic kidney disease. 
TRADITIONAL RISK FACTORS 
Advanced age 
Male sex 
Systemic hypertension 
Diabetes  
Dyslipidemia  
Menopause  
Insulin resistance  
Sedentary life style 
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Family history of cardio vascular disease  
LVH 
 
RISK FACTORS CAUSED BY CKD 
 Albuminuria 
Homocysteine 
 Lipoprotein (a) and apo (a) isoforms 
 Lipoprotein remnants 
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 Anemia 
 Disordered bone /mineral metabolism 
 Increase in the volume of extracellular fluid 
Electrolyte imbalance 
 Oxidative stress 
Increase in Inflammatory mediators 
Protein energy wasting 
Prothrombotic mileu 
Endothelial dysfunction 
Toxins of uremia 
Hypotension related to dialysis 
 Sympathetic activation 
Hypertension 
Hypertension is one of the most serious complications of chronic kidney 
disease. It occurs in more than three fourth of patients with end stage renal 
disease and constitutes in major for the emergence of ischemic heart disease and 
congestive heart failure [15]. 
Factor contributing hypertension in uremia 
1. Salt and water retention 
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2. Enhanced activity of renin angiotensin system 
3. Excess aldosterone secretion 
4. Increased sympathetic tone 
5. Diminished production of vasodepressor hormone 
6. Excess release of vasoconstrictor natriuretic factors. 
7. Stiffening of the arteries because of sclerosis of the tunica media  
8. Erythropoietin therapy. 
 In patients with CKD, GFR and albuminuria are proportionate to the 
increase in the systolic blood pressure. High levels of blood pressure in dialysis 
dependent  patients  is seen in patients who are young, who are having lesser 
adherence to the advised dialytic regime or who have increased weight gain in 
between the dialysis sessions [16,17,18,19]. Hypertension is also prevalent 
among post transplant patients. Apart from all the usual factors associated with 
CKD causing hypertension post transplant patients have an increased risk due to 
therapy with calcineurin inhibitors which exert a vasoconstriction mechanism 
Hypertension is foremost cause of left ventricular hypertrophy in patients 
with chronic kidney disease. Left ventricular hypertrophy and myocardial 
fibrosis can also be caused by non hemodynamic factors like angiotensinogen II, 
paratharmone, endothelin, aldosterone, increased sympathetic discharge. Left 
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ventricular hypertrophy is consistent with hypertension, ventricular arrhythmia 
probably reflecting that the most likely mechanisms are either due to 
subendocardial ischaemia, alterations in vasodilator reserve or structural 
changes in coronary micro circulation. 
Hyperglycemia 
In general population with CKD, CVD is more prevalent among individuals 
with diabetes those without diabetes. However it is not known hyperglycemia 
per se causes CVD in either population. Approximately 30% of all patients who 
begin maintenance dialysis therapy have diabetes. 
The American Diabetic association recommends lower blood glucose levels to 
normal or near normal in patient with type1 and type2 diabetes to reduce the 
risk for  development and progression of renal, retinal and neurologic disease 
and to improve  dyslipidemia. In the CKD patients with micro albuminuria, 
strict glycemic control may slow the progression of renal disease. The most 
significant factor contributing for CVD, in diabetes is Coronary Artery Disease 
{CAD}. In patients with advanced complication like CAD, intensive glycemic 
control may not be effective [20]. 
 
 
34 
 
Hyperlipidaemia 
The prevalence of hyperlipidaemia in CKD is greater than in general population 
even though the type of abnormality varies. Hypertriglyceridemia is the most 
common lipid abnormality in ESRD patient and is often found in association 
with a low HDL-C. Elevated total or LDL cholesterol levels are associated with 
CVD in CKD. There is also elevation in levels of other lipids such as IDL-C, 
VLDL-C, Lipoprotein-a[Lp(a)]. Patients with elevated levels of Lp(a) are at an 
increased risk of  CVD mortality. 
 In patients on hemodialysis, lower levels of serum total cholesterol are 
associated with unfavorable outcomes. The lower levels of cholesterol in these 
patients are accounted by malnutrition and inflammation. 
 
 The ratio of albumin to creatinine in urine is an important factor linked 
with the cardiovascular disease and events. Studies have found out not only 
micro–albuminuria but also low grade albuminuria (even lesser amount than 
microalbuminuria) is associated with cardiovascular disease.  Albuminuria is a 
documented risk factor also for the progression of CKD. This dual effect of 
albuminuria is actually the marker of widespread dysfunction of the 
endothelium.  Chronic kidney disease is defined as cardiovascular disease risk 
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equivalent, and all the stages of chronic kidney disease are considered in the 
highest risk group [4, 21]. 
 
Insulin resistance  
 Insulin resistance is a part of the metabolic syndrome which is an 
important factor associated with increased CVD risk.  In CKD owing to the 
presence of inflammation it is suggested that metabolic syndrome is linked in 
patients with varying stages of CKD [22]. The insulin resistance is particularly 
documented in the beginning stages of CKD. 
Homocysteine 
Elevated Homocysteine levels appear to increase the risk of development of 
cardio vascular disease in general population. Homocysteine levels are elevated 
in most patients with CKD. As per studies elevated homocysteine appears to be 
associated with risk factor for cardiovascular morbidity and mortality in patient 
with ESRD. But larger studies are needed for confirmation. It is proposed that 
elevated levels of homocysteine may cause injury to vascular endothelium and 
may cause a hypercoagulable state.  
Increase in the volume of ECF 
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 Increase in Plasma volume owing to sodium and water retention can 
occur in every stage of CKD particularly in ESRD or dialysis dependent 
patients. This volume expansion leads to hypertrophy and dilatation of the left 
ventricle. The importance of this lies mainly in dialysis patients whom the inter-
dialytic weight gain affected mainly by this volume expansion is responsible for 
the blood pressure to rise. In a study it was shown that rate of fluid removal by 
dialysis was an independent factor affecting survival of the patients[23]. 
Reduced levels of albumin 
 Hypoalbuminemia is seen as predictor of outcomes in dialysis dependent 
patients. This relationship is even more evident in patients undergoing 
peritoneal dialysis rather than hemodialysis. The reduced levels of albumin are 
associated with the left ventricular enlargement, and there is increased incidence 
of cardiac failure and coronary artery disease[24]. In post transplant individuals 
the levels of albumin alone particularly hypoalbuminemia is an independent risk 
factor for cardiovascular diseases. 
Increase in inflammatory markers 
   In patients with CKD, the inflammatory marker- C- reactive protein 
is been seen as an important risk factor in development of atherosclerosis. C- 
reactive protein (CRP) 
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 Is an effective stimulator of monocytes to produce tissue factor.  
 Can activate the complement system 
 Binds and causes aggregation of  LDL and VLDL by a calcium dependent 
mechanism 
The causes for CRP elevation are of debate.  The proposed sources include 
 Sub clinical or unidentified infections 
 Dialysate fluid’s bio-incompatibility 
 Endotoxins back filtered in the process of dialysis  
 It is studied that CRP has as an independent association with the number of 
atherosclerotic plaque in HD patients. It is also associated with the thickness of 
intima & media of arteries in pre dialysis population.  In a particular group of 
patients who were on hemodialysis it has been studied that patients with higher 
levels of C- reactive protein have 5 times increased risk of CVD death [ 25]. 
Oxidative stress 
 It occurs due to alteration in balance between production of reactive 
oxygen species and radical anti oxidative processes. The important free radicals 
include 
 Superoxide 
Hydrogen peroxide and 
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 Hydroxyl ions 
These molecules provide protection against various neoplastic cells and 
pathogenic agents [26, 27]. The neutralization of these molecules are done 
either by 
 Enzymatic elements 
 Glutathione peroxidase 
 Superoxide dismutase 
  Or by non enzymatic elements namely 
 VitaminE  
 VitaminC 
 Se 
 Zn  
The increased oxidative stress is due the increase in lipid peroxidation, 
reduction in substances enhancing resistance against oxidation and reduced 
levels of reducing substances. Dialysis also can increase the level of stress 
because the anti oxidant molecules may get removed and or due to the 
stimulation of the free radicals via the dialytic components. 
 
 
39 
 
Prothrombotic mileu 
 Even though patients with CKD will have reduced platelet aggregation 
and prolongation of bleeding time, elevated levels of many pro thrombotic  
factors particularly increased levels of fibrinogen is also seen in them and is 
associated with increased coronary events[ 28, 29] . This leads to increased risk 
of CVD in such patients.   
Physical inactivity 
Physical activity is reduced among the patients with CRF especially patients 
with ESRD. As in general population exercise appears to improve the well 
being in patients with CKD. The association of physical activity and CVD in 
CKD has not been carefully studied. 
Hyperparathyroidism 
Secondary hyperparathyroidism is virtually universal in dialysis patient. The 
Pathophysiological mechanism due solely to high serum phosphorus levels. The 
risk of vascular and soft tissue calcification rises sharply with higher levels of 
serum phosphorus. Calcification can occur in coronary and peripheral arteries 
and in the myocardium [30]. In the order of strong association with mortality it  
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has been studied and shown that high serum phosphorus levels and the presence  
of elevated levels of calcium – phosphate product were strong predictors, while 
hypocalcemia alone constituted an intermediate risk and high levels of 
parathyroid hormone alone carried the lowest risk.  
 
Hemodialysis related hypotension 
 HD therapy can lead on to hypotension and subsequent hypoperfusion in  
around one-tenth to one-third of the patients. Hypotension during dialysis is 
either reduction of systolic BP less than 100 mm of Hg or a symptomatic 
lowering of systolic BP more than twenty mm of Hg. The complications include 
cerebral hypoperfusion and or ischemia to myocardium. In a study it was found 
that patient groups who had lowered their systolic BP less than 110 mm of Hg 
were at twice the risk of mortality compared with group having systolic BP of 
140mm of Hg to 149 mm of Hg post dialysis. 
 The mechanism underlying this scenario is the altered balance between 
the volume of fluid that is been removed and vascular compartment’s refilling 
capacity. 
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PATHOPHYSIOLOGY OF CARDIOVASCULAR 
ABNORMALITY 
Left ventricular hypertrophy 
LVH is highly prevalent in CKD through stages III to V and it represents 
adaptative mechanism that occurs in response to a chronic increments in 
myocardial work requirement [30]. 
Pathogenesis 
LVH may be thought of as resulting from one or the other, the LV 
pressure overload or the volume overload to the left ventricle. Pressure overload 
or systolic overload occurs often due to hypertension, aortic stenosis, due to 
higher after load to the heart and reduced arterial compliance from 
arteriosclerosis. Volume overload or diastolic overload is often caused by 
anaemia, which results as the counteractive mechanism of the heart to increase 
the delivery of oxygen to peripheral tissues [31, 32]. 
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 Initially the effect of LVH seems to be useful. Even though there is either 
higher intraventricular pressure or volume overload or both, there will be 
structural alterations in the heart that permits an increased work capacity while 
preserving the tensile strength of the ventricular wall which enables to conserve 
energy favorably [33]. This can be compared to physiological changes that 
occur in pregnant women in last trimester, athletes and in normal development 
of children through adolescence.  
 As the course of the disease progresses the benefits turns out as 
detrimental as there is loss of myocytes because of the chronic mismatch 
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between the production and utilization of energy leading to energy deficit over a 
long term [34, 35]. Pathogenesis of this energy deficit is caused by various 
factors such as 
 Reduction of  capillaries in myocardium 
 Decreased blood supply to sub endocardium [36]. 
 Increased aortic and large to medium arterial stiffness [37]. 
The papillary muscles get lengthened and along with myocyte 
rearrangements, apoptosis there is also impairment of the myocardium to 
generate adequate force. There is increased expression of certain proto 
oncogenes that favor the fibroblastic activity leading to fibrosis of myocardium 
[34, 38]. All these changes promote the diastolic dysfunction and various 
electrophysiological derangements. The myocardial fibrosis, which predisposes 
to conduction abnormalities along with the decelerated sarcoplasmic reticular 
calcium ion reuptake predispose to arrythmogenic potential. The above said 
factors along with stiffening of ventricular wall predisposes to diastolic 
dysfunction. 
An Indian study in the year 2003 done by Dhangri P and his colleague in 
60 patients divided into 2 groups of 30 each into mild to moderate chronic  
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kidney disease (S.Creatinine 1.5-6.0 mg/dl) and advanced chronic kidney 
disease (S. Creatinine >6.0mg/dl) found in mild to moderate group 40% patient 
had LVH, and in advanced group 97% of   patients had LVH [32]. 
Another study done in India by SA Kale and his friends in a prospective 
study including 161 patients from 1997-1999 with mean age group of patient 
being found left ventricular disease was found in 105(65.2%) patients. Systolic 
dysfunction was noticed in 42(37.8%) patients. Left ventricular hypertrophy 
was seen in 88 (54.7%) patients [39]. 
Zocalli in his study found LVH in ESRD patients is a multifactorial origin 
like hypertension, anaemia, hyperparathyrodism, chronic volume expansion, 
inflammation, hyperhomocysteinemia, increased sympathetic activity [ 40]. 
Cardiac failure 
    Systolic dysfunction  
 The systolic function of patients with excessive volume overload and 
patients with pre existing cardiac disease is reduced. Approximately fifteen 
percent of patients during the initiation of dialysis have systolic dysfunction 
[41]. One of the causes of this systolic dysfunction is the overload 
cardiomyopathy which causes reduced contractility of the cardiac musculature. 
This overload cardiomyopathy has a poor prognosis when compared with the 
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concentric LVH or the left ventricular dilatation without systolic dysfunction 
[42]. 
 Another important mechanism contributing to systolic dysfunction in 
patients with CKD includes the uremia which causes reversible myocardial 
dysfunction. As the level of uremia increases the force of contraction of the 
myocyte is proportionally reduced. The renal transplantation can reverse the 
systolic dysfunction in dialysis patients. 
Impaired Diastolic function 
  Patients with CKD particularly patients on HD mostly will have some 
degree of diastolic dysfunction. The degree of diastolic dysfunction is not high 
as seen with cardiomyopathy but higher than  the diastolic dysfunction seen 
with hypertensive heart disease [43, 44, 45]. This dysfunction causing the 
impaired filling of LV is caused by the intra mural fibrosis. This causes 
stiffening of the left ventricular wall which in turn can precipitate pulmonary  
edema even when there is a mild change in the volume status [46]. This 
stiffening per se can cause the hypotension and hypoperfusion when there is 
volume depletion leading on to reduced left ventricular filling. 
 In a study done in Canada using echocardiographic evaluation twice in 
dialysis  patients  one year apart it was found that increased LV mass is an 
46 
 
independent predictor of cardiac failure and mortality. There is also evidence 
that the management of hemodynamic factors can reduce the left ventricular 
hypertrophy and death. 
                              
Ischemic heart disease is frequently present in patients with end stage 
renal disease. The development of atherosclerosis in patients with CKD is 
multifactorial and begins before kidney failure. There is a higher occurrence of 
critical stenosis in coronary vessels in patients with CKD. Vessel wall damage 
predisposing to the development of atherosclerosis is caused by a variety of 
factors 
 Activation of endothelium and injury caused by chronic uremia [ 47, 48] 
 Endothelial activation brought about by the increased shear stress [49]. 
  Endothelial activation brought increased tensile stress of the vessel wall 
[49].   
 Production of the various growth factors  in response to the stress 
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All these factors finally contribute to the cellular death of endothelium, 
extracellular matrix production and deposition. Apart from the activation and 
injury of the endothelium certain other factors predispose to the alteration in 
coronary arteries in patients with CKD. They are 
 Increase in the levels of procoagulant factors 
 Increase in the oxidative stress effected by the reduced anti oxidant and 
increased reactive oxygen molecules. 
  Various lipid abnormalities promoting atherosclerosis. 
 Increased insulin resistance and irreversible changes in extracellular 
substrates effected by elevated blood sugar levels 
 Imbalance between inflammatory mediators & inhibitors 
 Endothelial effects of elevated homocysteine levels. 
 Elevated levels of CRP 
 Calcium deposition in the wall of vessels. 
  
  Patients with this type of coronary artery disease tend to have 
ischemic symptoms even without having critical coronary disease. The origin of  
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these symptoms is likely to be because of the cardiomyopathy and  
microvascular pathology. The left ventricular hypertrophy predisposes to this 
kind of heart disease in dialysis patients. The hypertrophy is responsible for the 
increase in the myocardial oxygen demand which requires further dilatation of 
the coronary vasculature to effect adequate blood flow. As this process is not 
amenable if there is pathology in large or small vessels, there is occurrence of 
ischemia. Few other factors have been implicated in this type of heart disease 
are.  
 
 Cardiac Myocyte-capillary mismatch 
 Small vessel muscle hypertrophy and abnormalities in endothelium 
associated with LVH and uremia [ 50, 51] 
 Predisposition to ischemia brought about by the improper 
regulation of phosphate compounds. 
S patrick et al in their study found 28 to 41% of patients have ischemic heart 
disease [42]. 
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TABLE 3: FACTORS CONTRIBUTING TO ISCHEMIC HEART DISEASE 
Lintrine et al described that among stage 5 CKD cardiac failure is 
common. The reciprocal causation between the renal failure and cardiac failure 
is a cyclical event and also occurs due to the common risk factors that exists. 
The cardiac failure imparts a poorer prognosis in stage 5 CKD and dialysis 
patients, even subtle dys function of the heart is an independent predictor of 
mortality in renal transplant patients. Few of the factors causing cardiac failure 
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in these patients like uremia, anaemia and volume overload could be improved 
by renal transplantation therapy [53]. 
Arrhythmias  
 In patients with CKD, particularly patients with ESRD and dialysis, there 
can be high occurrence of arrhythmia and sudden cardiac deaths. Factors 
predicting higher incidence and severity of arrhythmia include  
 Advancing age  
 History of cardiac disease 
 LVH 
 Treatment with digoxin 
The other important factor associated with the arrhythmias in patients on 
dialysis is the dialysis hypotension[54]. As far as for various dialysis procedures 
there is a study showing reduced occurrence of arrhythmias in people 
undergoing peritoneal dialysis rather than HD. It was stated that these effects 
may be due to absence of post dialysis hypotension & reduced occurrence of 
hyperkalemia in peritoneal dialysis.  
The presence of left ventricular hypertrophy & coronary artery disease as 
well as the alterations in the various serum electrolyte concentrations occur in  
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the context of CKD, providing the basis for arrhythmias. Various studies have 
found out various atrial and ventricular arrhythmias can occur. Some of the high 
grade arrhythmias prevalent in a study include  
 Ventricular tachycardia 
 Ventricular couplet& 
  Multiple ventricular ectopics[55].  
These arrhythmias’s presence indicates high chance of sudden death and 
mortality. 
  
There can be valvular leaflet and annular calcifications in the mitral and aortic 
valves due to the dystrophic calcifications [56]. The occurrence of aortic 
valvular calcification occurs a decade or two earlier. The aortic sclerosis is 
considered to be related to high CVD mortality.  The valvular calcifications are 
associated with the conduction disturbances, rhythm disturbances, regurgitant 
lesions and peripheral vessel disease. The reduced survival because of valvular 
calcifications can be brought about by 
 LV systolic dysfunction 
 Severe calcification[56]. 
 Mitral valve insufficiency. 
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 The increased LV after load is linked with higher incidence of the CVD 
burden [57, 58]. The reasons for the increased after load include increased 
vessel stiffening, increased sympathetic tone & autonomic derangements.  
  In chronic kidney disease there is an accelerated ageing process of the 
vessels leading to arteriosclerosis and vascular dilatation. These changes 
predispose to the so called faster pulse wave velocity and systolic hypertension. 
Even in patients on dialysis tend to have a normal peripheral resistance, thus 
 reducing the chances of diastolic hypertension. So as a result there is widened 
pulse pressure which is also associated with the development of LVH [59]. 
Pericardial disease 
Pericardial disease in CKD is generally associated with stage 5 CKD. 
Pericarditis is the consequence of an inflammation of the pericardium, the 
serous membrane enclosing the heart and the root of the great blood vessels. 
Pericarditis occurs in both acute and chronic renal failure patient. Over the past 
40 years with the advent of dialysis therapy the incidence of clinically apparent 
pericarditis has decreased from 50% --60%. The reason for occurrence of this 
entity is thought to be because of the increase in various toxins of uremia. This 
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thought originated as the pericarditis resolves with intensive dialysis regimen. 
Pericarditis is frequently seen in peritoneal dialysis patient than it occurs in 
haemodialysis patient. The difference has been attributed to a higher clearance 
of ‘middle molecule’ in peritoneal dialysis. Pericardial effusion frequently 
complicates pericarditis but cardiac tamponade is rare. Constrictive pericarditis 
is rare in dialysis patient. Small pericardial effusion is found in 15-20% of 
patient of stable asymptomatic patient .It most commonly manifests as acute 
uremic or dialysis-associated pericarditis although chronic constrictive 
pericarditis may also be seen.             
                              
      Transthoracic echocardiogram showing pericardial effusion. 
 Dialysis pericarditis describes patients who develop clinical 
manifestations of pericarditis after 8 weeks of initiation of this kidney 
replacement therapy [60]. It is associated with the poor response even with the 
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intense dialysis regime. Avoidance of heparin is done during dialysis in order to 
prevent cardiac tamponade. 
 
INFECTIVE ENDOCARDITIS        
Infective endocarditis (IE) is a relatively common complication of hemodialysis 
when compared to rates in the general population. This likely reflects several 
factors, including 
 the relatively high incidence of bacteremia, 
 common use of  dialysis catheters, and  
 the high prevalence of pre-existing valvular abnormalities. 
The bacteremia in patients undergoing HD is mainly because of the catheter 
access site infection. The left sided valves are more involved, among them 
mitral valve is the most commonly affected there should be a suspicion of 
infective endocarditis when there is  
  Indication of persistent infections beyond catheter removal/antibiotics 
 Occurrence of metastatic abscesses 
 Positive blood culture for staph aurues 
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Trans oesophageal echo is very sensitive as high as hundred percent. Therapy of 
IE should be based on culture reports and should be continued for at least 1 
month in HD patients. However the death rate is higher in ESRD[61] patients. 
 
 
 In patients with CKD particularly among stage 5 CKD, there is some 
degree of resistance in baroreceptors. This manifests in the exercise ECG as a 
restriction in maximum pulse rate and limited exercise ability. The cause for this 
may be attributed to 
 Increasing age 
 Hypertension  
 Volume overload 
Increased sympathetic activity is common in patients with stage 5 CKD. The 
relationship is proved by the nephrectomy of diseased kidneys. There is 
downregulated vasopressor response to sympathetic activity which is an 
important factor that accounts for dialysis-hypotension.  
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INVESTIGATING CARDIAC DISEASE IN CKD 
 LVH associated ECG changes are prevalent in CKD patients, thus making 
the ST segment depression in routine ECG less predictable of CAD. Many 
electrolyte and fluid alterations take place that produce diagnostic dilemma in 
ECG. Particularly HD causes the prolongation of QTc, QT dispersional increase 
and QRS segment abnormalities. 
 Troponins, the cardiac biomarkers are moderately increased in CKD. 
However their importance is felt when there is a rise from the baseline. High 
levels of troponin-t are a potent marker of adverse events. Apart from these 
BNP can be used as a reliable predictor for outcomes. 
 
TABLE 4: CAUSES OF ELEVATED CARDIAC TROPONIN IN CKD 
PATIENTS. 
57 
 
   
ECHOCARDIOGRAPHY 
Echocardiography in both Two-dimensional and M mode gives idea about the 
left ventricular hypertrophy & systolic dysfunction.  The amount of   LVH is 
detected by increased free wall thickness of left ventricle or via the Left 
Ventricular mass index calculation. Echocardiography is also useful in valvular 
and pericardial pathologies.  
The mass index of Left Ventricular before the dialysis is higher than mass index 
measured after the dialysis even though the actual Left Ventricular mass 
remains the same .this due to the removal of fluid during dialysis causing a 
decrease in the Left ventricular internal diameter. For this reason 
echocardiography must be done after achieving the so called ‘ base weight ’.it it 
is the minimum weight which the patient can be in without muscular cramp or 
dialysis associated  hypotension. 
Diastolic dysfunction can be assessed via Doppler analysis of diastolic flow 
across the mitral valve. Physiologically after the opening of the valve, there is 
relaxation of ventricle, with sudden rise in flow causing the E peak or the early 
peak, than atrial systole occurs causing the A peak or the atrial peak. The 
stiffening of the hypertrophied Left Ventricle causes a small E peak, and a large 
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A peak, when the function of the left atrium is normal. Diastolic dysfunction is 
represented by a reduced E/A ratio. 
Stress echocardiography using Dobutamine can be used for screening CKD 
individuals to find out CAD. It is used to find out the underlying systolic reserve 
even in patients with systolic dysfunction. This investigation has a good 
specificity and sensitivity exception being female sex and older age[62]. For 
patients who cannot tolerate exercise it is preferred over scintigraphy. For 
patients undergoing dialysis this investigation has shown to have a very high 
negative predictive value [63]. 
NUCLEAR SCINTIGRAPHY 
Systolic function and ischemic changes can be detected by nuclear scintigraphy. 
For the proper evaluation via this technique the valvular insufficiency should 
not be there. With normal valvular function estimation of systolic dysfunction 
during exercise and rest can be done accurately. 
Either by the use of 99mTc-labelled thalium, methoxyisbutylisonitrile,‘ MIBI ’, 
or metiodobenzylguanidine ‘ MIBG ’ or exercise  it is used in screening prior to 
transplantation and in cases of uncertain diagnosis of CAD. Hypotension, very 
high blood pressures, LVH  causing reduced perfusion , blunting of tachycardia 
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response because of autonomic neuropathy are significant obstacles to this type 
evaluation[64], and may cause improper evaluation or may cause adverse 
results. 
Coronary Angiography  
This technique is gold standard for the diagnosis of CAD.  There is always the 
risk of contrast nephropathy with this procedure which offers hindarance. The 
risk of cholesterol embolism is also there. As there is more occurrence of 
asymptomatic CAD, the American society of transplants physicians suggests the 
screening can be avoided only in the patients who are at lowest risk for CAD 
[65]. 
EBCT  
EBCT, Electron-beam ultrafast computed tomography is used to determine the 
coronary atherosclerosis with the help of coronary arterial calcification. This 
technique takes into account that coronary calcification is an important marker 
of atherosclerosis but in CKD patients there is a vascular calcification 
widespread and severe in degree. But the use of this technique is very useful due 
to the fact that the higher the accumulation of calcium in atheroma or vessel 
wall poorer the prognosis according to the recent evidences [66, 67]. 
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Duplex Ultrasonography and Doppler Flow Imaging  
The different vessel beds have different waveforms, pathology is indicated by 
the change of the normal waveform.. Generally pathological arterial segment 
show spectral broadening of waveforms, the increased velocity of flow at the 
site of vessel stenosis and there will be  pre stenotic waveforms above and post 
stenotic waveforms below the obstructed segment. 
Ankle Brachial Index 
The ankle brachial index provides useful screening test for arterial disease of the 
lower limbs. The procedure uses continuous-wave Doppler interpretation of the 
arm’s blood pressure and ankle blood pressure. The ankle brachial index is 
calculated by  
Ankle brachial index = ankle systolic BP ÷ arm	systolic	BP 
The index is usually taken twice before and after exercise. Absence of pain 
throughout the exercise period rules out pathology in vessels of lower limb 
vascular claudication. Ankle-brachial index ranges from 1.0 to 1.1 in normal 
individuals at rest. Progressive decrements indicate worsening, often multi level, 
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arterial stenosis. A resting level of ≤ 0.25 indicates severity of disease [68] but 
the important predictor is the post exercise reduction in the index. 
MRI and Angiography  
These techniques are particularly important in dissection of arteries and imaging 
the vascular morphology. These techniques are much useful in the imaging of 
renal vasculature and mesenteric vasculature when there is risk of contrast 
nephropathy or cholesterol embolism. 
Intravascular Ultrasonography 
It is mostly used to determine the morphology of the vessel and morphology of 
the plaque used in adjunction with intervention technique of vessels. The 
vascular lumen can be displayed using 3-dimensional re-construction methods. 
As there is reduced interference from the inter positioned structures and 
vascular calcification this technique is more sensitive than the routine 
ultrasonography. 
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Electrocardiogram 
Muirhead and others demonstrated electrical activity of the heart during later 
period of 19th century, following which there was direct recording of cardiac 
potentials by Waller in 1886 [69]. 
William Einthoven first introduced the term “electrocardiogram” by the 
year 1893 which is used till date worldwide for the recording of electric activity 
of the heart. String Galvanometer which was invented by William Einthoven in 
1901 provided a consistent and direct method for registering electrical activity 
of the heart [69]. 
           
 String galvanometer which was used to record ECG initially 
 After the year 1910 string galvanometer become very popular in clinical 
practice. Subsequent ECG became the first and most common bioelectric signal 
to be computer processed and most commonly used cardiac diagnostic test.  
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ELECTROCARDIOGRAPHIC CHANGES IN CKD 
The abnormal resting ECG and exercise ECG are brought about by the ever 
so increased occurrence of LVH among CKD patients. ST-T changes along with 
the increase in the PR interval and QRS duration are seen in patients who are 
dialysis dependent. These patients also exhibit more ECG changes during 
dialysis due to changes in electrolyte transfer between intra and extra cellular 
compartments. However the occurrence of classical ECG changes of acute 
coronary ischemia indicate occurrence of  MI and unstable angina. 
The risk of arrhythmia, sudden cardiac arrest and death is higher in patients 
undergoing maintenance HD. The factors that are associated with the 
occurrence of arrhythmias in these patients include 
 The alteration in the serum electrolytes 
 Alteration in the volumeic status 
  Blood pressure  
 Underlying CVD 
 various medicational usage 
There is a markedly increased rate of cardiac events and decreased event free 
survival rate in non diabetic dialysis patients than general population [70].  
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  At the time of initiation of dialysis, many of CKD patients will have ischemic 
heart disease. ESRD patients with coronary artery disease either symptomatic or 
asymptomatic are at increased risk for arrhythmias and Sudden Cardiac Death. 
The risk is exaggerated in the presence of anaemia and left ventricular 
hypertrophy, which are commonly encountered in patients with ESRD and 
dialysis dependant.  
The occurrence of ECG abnormalities and the occurrence of new arrhythmias 
and silent ischemia to myocardium are related to the presence of Coronary 
artery disease, and is related to the duration of dialysis. Serious, life threatening 
ventricular arrhythmias and silent ischemia of myocardium has been noted in 
patients on dialysis [71].  
 Factors contributing to increased occurrence of arrhythmias include   
 compromised myocardium  
(Because of either underlying Coronary Artery disease, decreased 
coronary blood flow, or  the effects of uraemia on myocardium), 
 increased QTc interval or dispersion,  
 Abnormalities in levels of electrolytes, 
  Dialysis hypotension,  
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  presence of LVH (present in most of the patient on dialysis), and  
 Autonomic dysfunction (with or without diabetes). [25]  
Patients on Dialysis have frequent electrolyte abnormalities like fluctuation in 
the levels of potassium, ionized calcium, magnesium, and other divalent ions. 
Patients on HD have wide fluctuating levels of potassium and bicarbonate.  
These fluctuations are due to  
 Intermittent nature of procedure, promoting high interdialytic variation 
 the level of potassium and calcium in the dialysate fluid used  and  
 Incomplete adherence to dietary regimes directed towards the control of 
calcium-phosphate product. [72].  
Soman and his colleague divided 9,554 patients into 5 groups based on 
creatinine clearance, where mean age group of patients being 63.4±13.8 years 
and they observed atrial fibrillation in 4.1 to 9.4%, complete heart block in 0.7-
3.5%, RBBB in 3.5-7.1%, LBBB in 3.6-8.3% and LVH in 7.1-18.5%. Unstable 
angina was documented 33.2%-39.9% in different groups of chronic kidney 
disease [73]. 
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Graham in his study in 2004 on 296 patients found by ambulatory ECG 
recording higher prevalence of supraventricular tachycardia, ventricular 
tachycardia and ectopics. The chronic renal insufficiency cohort study done by 
Soliman and his friend in on 3,267 patients with mean estimated glomerular 
filtration rate of 43.6±13.0 found atrial fibrillation as the most common 
arrhythmia in CKD patients, nearly one in every five participants had evidence 
of atrial fibrillation [74]. 
Abe in his study on 221 patients noticed 72 patients had sinus rhythm, 2 patients 
had atrial fibrillation, 29 patients had ventricular premature complex, ST-T 
changes seen  in 43 patients [75]. 
In a study done by A.S Menon et al [9] and Krivosheiv[76] et al the 
commonest electrocardiographic abnormality was lateral wall ischemia, left axis 
deviation with left ventricular hypertrophy, prolonged QT interval, p.mitrale and 
intraventricular conduction defect. 
The Electrocardiographic manifestation of the left ventricular hypertrophy 
due to systolic overload [77]. 
1. Abnormalities of the QRS complex 
· Increased magnitude of QRS deflection. 
· Attenuation of the small q wave in left oriented leads. 
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· An increased time in left ventricular activation time. 
· A small equiphasic complex in lead AVF. 
· Counter clockwise electric rotation. 
2. Abnormalities of ST segments and t waves 
T wave may be inverted in lead V5, V6 lead I and AVL, upright in 
right oriented leads. The associated ST segment in the left oriented leads is 
usually minimally depressed. This is an indication of hypertrophied left 
ventricular strain, probably the expression of relative ischemia. 
3. left sided chest leads showing inverted u waves. 
4. Left atrial enlargement. 
5. Abnormality of the QRS and T wave. 
Early and uncomplicated left ventricular hypertrophy causes no change in the 
direction of the mean plane QRS vector. With relatively long standing left 
 ventricular hypertrophy, the QRS axis begin to deviate to the left side. 
 The mean frontal T wave vector is directed to the right reflecting very 
  compromised left ventricle. 
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  The Electrocardiographic manifestation of diastolic overload. 
 
 1. Increase  in  the R wave voltage. 
 2. Deep  Q waves. 
 3. Relatively tall symmetrical T wave. 
 4. Minimally elevated S-T segment. 
 5. Inverted U waves in the left precordial leads. 
  The Electrocardiographic manifestation of the cardiomyopathy 
   They include 
 Sinus tachycardia 
 Ventricular arrhythmia 
 Left atrial enlargement 
 Non specific ST-T wave changes 
 Intra ventricular conduction defects 
 Low voltage  
 Effect of electrolyte disturbance on ecg. 
Uraemia presents with manifestation of hypocalcaemia and associated with 
hyperkalaemia and or acidosis. The hypocalcaemia causes a prolong ST 
segment and there by the QT interval. The hyperkalaemia causes tall T waves. 
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The prolongation of QT interval is inversely proportional to the level of serum 
calcium. QT interval in hyperkalaemia is either normal or actually decreased. If 
the hyperkalaemia is associated with hypocalcaemia the QT interval may be 
prolonged. 
The QT interval is the interval beginning from the Q wave to the end of T wave. 
The QT interval shortens with tachycardia and prolong with bradycardia. It is 
thus evident that QT interval cannot be viewed in absolute term but must be 
corrected to the effect of associated heart rate. 
Drechsler Christiane et al in his study found atrial fibrillation in 8 to 12% of 
patients, signs of MI in 13 to 17%, LVH in 12 to 14%, ventricular conduction 
defect in 7 to 8% of patients in CKD patients with different ranges of 
HBA1c[78]. 
Graham27 with his collegue observed prolongeded QTc duration and increased 
QT dispersion was associated with reduced kidney function [79]. 
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4. MATERIALS AND METHODS 
Study design: 
 This study is a single center non randomized prospective study meant to 
study the electrocardiographic changes in patients with chronic kidney disease. 
Study period: 
  Consecutive patients of chronic kidney disease admitted in thanjavur 
medical college hospital during the period of 8 months between January 2014 to 
august 2014 were taken up for the study. 
Inclusion Criteria  
• Chronic kidney disease for more than 3 months.  
• Reduced Kidney size bilaterally. 
Exclusion Criteria  
 Documented ischemic heart disease. 
 Congenital heart disease. 
 Valvular heart disease. 
  Age less than 18 years.  
Study centre: 
 This study was carried out in Department of Medicine, Thanjavur 
Medical college Hospital, Thanjavur, Tamil Nadu. 
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 All cases were admitted and examined in detail in the wards and clinical 
data was recorded in the proforma annexed herein. All cases were followed till 
discharge or death. 
Clinical details: 
 Personal particulars like age, sex, duration of illness, presenting 
complaints, relevant history, past history, treatment history, clinical signs and  
symptoms were recorded. 
Clinical examination: 
 Examination was done in a detailed manner and vital signs, weight, were 
recorded and systemic examination was carried out. 
ECG monitoring:  
 ECG was taken in all cases after admission. Routine conventional limb 
leads, chest leads and long strips were recorded. Continuous cardiac monitoring 
was done in some needful patients.   
 Lab investigations: 
1.  a. Urine  
PH, 
 Specific gravity, 
 Protein, 
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 Sugar, 
 Microscopy  
2. Blood  
 COMPLETE BLOOD COUNT 
 Random blood sugar, 
   FBS/PPBS,   
 Blood  Urea, 
 Serum Creatinine,  
 serum sodium , 
  serum potassium 
 Serum fasting lipid profile 
2.  Ultrasound Abdomen   
3.  Transthoracic echocardiography (ECHO)  
These investigations were carried out in all patients. 
eGFR calculation done using cockraft and gault equation. 
Data Analysis  
The patients’ data were collected prospectively and entered in the proforma 
(annexure). The data was digitalized in Microsoft excel software. Statistical 
analysis was done using SPSS 21 software. 
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 The categorical variables have been described as proportions and 
percentages. The continuous variables have been expressed as mean and 
standard deviation, as well as range. 
 The effect of various factors on presence of ECG changes and no ECG 
changes was analysed by unpaired ‘t’ test for continuous data. Chi – square test 
was used to compare the categorical data. P value < 0.05 was considered 
significant in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 The present study comprises
patients admitted to thanjavur m
to august 2014.  
SEX DISTRIBUTION 
TABLE: SEX DISTRIBUTION OF 75 CASES OF CKD
SEX 
Male 
Female 
In the present study 49(65%) persons were males and 26(35%)  
distribution among males: females was approximately 1.8
 
female
35%
74 
5. RESULTS 
 75 consecutive proven chronic kidney disease 
edical college and hospital during January 2014 
 
Number 
Percentage 
 
49 65% 
26 35% 
 
:1. 
male
65%
sex
 the sex 
 AGE DISTRIBUTION  
TABLE: AGE DISTRIBUTION OF 75 CASES OF CKD
  
S.no  
Age 
distribution
1 Below 20yrs
2 21 to 40yrs
3 41 to 60yrs
4 61yrs & above
 
 
In the present study the age variation was from 18 to 76
patients were in the age group of 41
(67%). The mean age of the study group was
 
21-40yrs
13%
75 
 
 
Number Percentage
 2 3% 
 10 13% 
 50 67% 
 13 17% 
 years. Majority of the
-60 years, which included 50
 50.3±11.5 years.  
< 20 yrs
3%
41-60 yrs
67%
> 60 yrs
17%
 
 
 
 patients 
 TABLE : DISTRIBUTION OF 75 CASES OF CKD BASED ON DURATION 
Particulars
3 to 6months
6 to 12months
Above 1year
The duration of the renal failure in our study group ranges from 3 months to 6 
years. The mean duration of
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OF ILLNESS 
 Number 
Percentage 
 
 48 64.0% 
 18 24.0% 
 9 12.0% 
 
 renal failure in the group was 6.9 months.
6 to 12 months above 1 year
Duration
 
 
 TABLE : DISTRIBUTION OF 75 CASES OF CKD BASED ON LEVELS OF 
Blood urea 
(in mg/dl) 
60 to 100 
101 to 150 
150 & above
The blood urea levels of patients with CKD enrolled in our study ranges 
from62-180 mg%. Maximum
blood urea levels in the range101
was 120.5±28mg%. 
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BLOOD UREA 
No.of patients 
(n=75) 
Percentage
 
22 29.3% 
43 57.3% 
 10 13.3% 
 number of patients (43 patients) (57%)had their 
-150mg% the  mean value of the study group 
101 to 150 150 & above
 
 
 TABLE: DISTRIBUTION OF 75 CASES OF CKD BASED ON LEVELS OF 
SERUM CREATININE. 
Serum creatinine
mg/dl) 
2 to 4 
4.1 to 6 
6.1 to 8 
8 & above 
The serum levels of creatinine of patients 
mg%. The mean value for serum creatinine levels
maximum number of patients(34 patients) i.e.(45%) were in the range of 4.1 to 
6.0 mg%. 
0
5
10
15
20
25
30
35
40
45
50
2 to 4
P
e
rc
e
n
ta
ge
78 
 (in No.of 
patients  
Percentage
12 16.0% 
34 45.3% 
12 16.0% 
17 22.7% 
in our study ranges from
 was 6.2
4.1 to 6 6.1 t 8 8 & above
 
 
2.2-20.2 
±3mg% with 
 TABLE: DISTRIBUTION OF 75 CASES OF CKD
eGFR 
(in ml/min)
Below 15
15 to 30
 30 to 60
The eGFR of CKD patients enrolled in our study ranges from4ml/ min t0 
33ml/min. maximum number of patients(
ml/min. the mean eGFR of the study group was
calculation was done using cockraft and gault formu
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 BASED ON eGFR
 
No.of patients Percentage 
 55 73.3% 
 19 25.3% 
 1 1.3% 
55 patients) (73%)had eGFR<15 
 12.8±5.4 ml/ min
la 
15 to 30 Above 30
eGFR
. 
 
. The eGFR 
  TABLE: NUMBER OF PATIENT
HEMODIALYSIS . 
 
 
 
In our study group among the 75 cases of CKD enrolled 
patients undergoing regular hemodialysis. These
hemodialysis constituted around 17% of the total study patients.
 
 
THERAPY
No 
HD 
80 
S UNDERGOING REGULAR 
there were about 13 
 patients in regular 
 
 
No. of patients 
 
Percentage 
 
62 82.7% 
13 17.3% 
 
 
No
Yes
  
TABLE: DISTRIBUTION OF 75 CASES OF CKD BASED ON LEVELS OF 
SERUM SODIUM. 
Serum 
Na(meq/L)
Below 120
121 to 135
136 to 145
In our study group patients were having serum sodium in the range of 117
meq/L. the mean for this study group is 132.3±5.9 meq/L. the maximum number 
of patients  (48 patients)were in the range 121 to 135 meq/L constituting to 64% 
of group. 
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No. of patients 
 
Percentage 
 
 3 4.0% 
 48 64.0% 
 24 32.0% 
121 to 135 136 to 145
 
-145 
  
TABLE: DISTRIBUTION OF 75 CASES OF CKD BASED ON 
SERUM POTASSIUM. 
Serum K+
(in meq/L
3.5 to 5.5
5.5 to 7
Above 7
 
The levels of potassium in CKD patients enrolled in o
to 8meq/L. maximum number of patients(56 patients) (75%)had serum 
potassium within the normal range . the mean po
meq/L. 
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) 
No.of patients 
 
Percentage 
 
 56 74.7% 
 17 22.7% 
 2 3.4% 
ur study ranges 
tassium value was5.1 ± 0.9 
5.5 to 7 above 7
K(meq/L)
LEVELS OF 
 
from 3.5 
 TABLE: DISTRIBUTION OF 75 CASES OF CKD BA
LEVELS. 
Lipid  MEAN 
Total cholesterol 183.4 
Triglycerides 181.1 
HDL 45.7 
LDL 94.3 
 
 
 In our study population 40% of patients had abnormal lipid profile with 
elevated TGL and Reduced HDL as the commonest abnormalities, both of them 
accounting to 23% individual
0.00%
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SED ON LIPID 
S.D. 
21.3 
29 
6.2 
17.6 
ly. 
HIGH LDL
LOW HDL
Lipid 
abnormality 
No.  of 
patients
High TC 7 
HIGH TGL 17 
High LDL 10 
Low HDL 17 
 
 
percentage 
9.3% 
22.7% 
13.3% 
22.7% 
 TABLE : CASES OF CKD 
LVH in ECG
Absent 
Present 
 
In our study group patients 
total 75 patients, constituting to 29% of study population
  
Present
29%
84 
with LVH in ECG. 
LVH 
 
No.of patients 
 
Percentage 
 
53 70.7% 
22 29.3% 
having LVH in ECG were 22  in number out of the 
. 
Absent
71%
LVH IN ECG
 
 TABLE: CASES OF CKD WITH LEFT ATRIAL 
LAE in ECG
Absent 
Present 
 
In our study group patients 
9 in number out of the total
66 out of 75 patients did not ha
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ENLARGEMENT 
 
No.of patients 
(n=75) 
Percentage 
 
66 88.0% 
9 12.0% 
having Left atrial enlargement  in ECG was present 
 75 patients, constituting to 12% of study population.
ve the Left atrial enlargement in ECG.
LAE
Absent Present
IN ECG.. 
 
 
 
 TABLE: CASES OF CKD WITH CHANGES OF CORONARY ARTERY 
DISEASE IN ECG  
Ischemic 
changes
Absent
Present
In our study group patients 
17 in number out of the total 75 patients, constituting to 23% of study 
population. 58 out of 75 patients did
 
 
  
Present
23%
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No.of patients 
(n=75) 
Percentage 
 
 58 77.3% 
 17 22.75 
having ISCHEMIC CHANGES in ECG was present 
 not have the ischemic changes 
Absent
77%
ISCHEMIC CHANGES
 
in ECG. 
 TABLE:  CASES OF CKD 
HYPERKALEMIA.  
Hyperkalemic
changes 
Absent 
Present 
 
In our study group patients having 
was present 9 in number out of the total 75 
study population. 66 out of 75 patients did not have the 
to hyperkalemia. 
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HAVING ECG FINDINGS OF HYPERKALEMIA
 No.of patients 
(n=75) 
Percentage 
 
66 88.0% 
9 12.0% 
ECG changes pertaining to hyperkalemia 
patients, constituting to 12% of 
ECG changes pertaining 
Absent Present
Hyperkalemi
a, 12
Hyperkalemia
 
 
 TABLE: CASES OF CKD 
Conduction 
disturbances
Absent 
Present 
 
 
 In our study group patients, conduction disturbances in ECG was present 13 
of the total 75 patients, constituting to 17
patients did not have the 
disturbances included intraventricular conduction delay and QTc prolongation.
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HAVING CONDUCTION DISTURBANCES
 
 
No. of patients 
 
Percentage 
 
62 82.7% 
13 17.3% 
% of study population.
conduction disturbances in ECG.
Absent Present
Cond 
Dis, 17.3
Conduction  Disturbances
. 
 
out 
 62 out of 75 
 Conduction 
 
 TABLE: CASES OF CKD 
 
Arrhythmia 
Absent 
Present 
 
 
In our study group patients
75 patients, constituting to 4% of study population. 72 out of 75 patients did n
have arrythmia in ECG. Two patients had premature ventricular contractions 
and one patient had atrial fibrillation.
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HAVING ARRHYTHMIA ON ECG 
 
No.of patients 
(n=75) 
Percentage 
 
72 96.0% 
3 4.0% 
, arrythmia in ECG was present in 3 out of the total 
 
Absent Present
Absent Present
 
ot 
 TABLE:  CASES OF CKD 
CORONARY ARTERY DISEASE.
Cad  
In ECHO
Absent 
Present
 
In our study group patients
disease was present 16 out of the 
population. 59 out of 75 patients did not have 
coronary artery disease. 
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WITH ECHOCARDIOGRAPHIC CHANES OF 
 
 
No. of patients 
 
Percentage 
(100%) 
59 78.7 
 16 21.3 
 echocardiographycally detected coronary artery 
total 75 patients, constituting to 21
echocardiographycally detected 
Present
Absent Present
 
% of study 
 TABLE: CASES OF CKD
ECHOCARDIOGRAPHY.
  
Pericardial 
Effusion
Absent 
Present 
 
In our study group patients
4 out of the total 75 patients, constituting to 5% of study population. 70 out of 
75 patients did not have echocardiographycally detected pericardial effusion. 
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 HAVING PERICARDIAL EFFUSION
 
 
 
No. of patients 
(n=75) 
Percentage 
 
71 94.7 
4 5.3 
 pericardial effusion in echocardiography 
Absent Present
Echo pe, 5.3
Echo pe
 ON 
 
was present 
 
 TABLE: CASES OF CKD WITH LEFT VENTRICULAR HYPERTROPHY 
IN ECHOCARDIOGRAPHY
Lvh in 
Echo 
Absent
Present
 
The eGFR of CKD patients enrolled in our study ranges from4ml/ min t0 
33ml/min. maximum number of patients
ml/min. the mean eGFR of the study group 
 
 
  
Present
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 No. of patients 
(n=75) 
Percentage 
 
 44 58.7 
 31 41.3 
 (55 patients) (73%) had eGFR<15 
was 12.8±5.4 ml/ min. 
Absent
LVH  by ECHO
 
 TABLE: SUMMARY OF 
 
 
 
 
 
 
 
 
 
 
 
In our study group the observed ECG changes were LVH in 29%, left 
enlargement in 12%, CAD 
abnormalities in 17%, arrhythmia in 4% of the total study population.
CHANGE 
 
LVH 
LAE 
ISCHEMIA 
HYPERKALEMIA
CONDUCTION 
ABNORMALITY
ARRYTHMIA 
NO CHANGES 
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ECG CHANGES 
in 23%, hyperkalemia in 12%, conduction 
LVH
LAE
ISCH CHANGE
ARYTHMIA
COND DIS
HYPERKALEMIA
NO CHANGE
NO.OF 
PATIENTS 
PERCENTAGE
22 29.3 
9 12 
17 22.7 
 9 12 
 
13 17.3 
3 4 
22 29.3 
atrial 
 
 
 
 TABLE: TOTAL NUMBER OF PATIENTS WITH ECG 
 
Particulars
No 
Yes 
Among the 75 patients with CKD only 29% of the study population had a 
normal ECG. The rest of the study group constituting 71% had abnormalities 
which were mentioned above
 
 
Present
71%
94 
CHANGES.
 
No. of respondents 
(n=75) 
Percentage 
(100%) 
22 29.3 
53 70.7 
.  
Absent
29%
ECG changes
 
 
  
Chi-square test comparing ECG changes with age
 
 
 
 
 
 
 
 
 
 
 
Based on the statistical analysis there was a correlation between the age and the 
Changes in ECG . With advancing age the changes in 
patients with CKD (p value=0.04)
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ECG were evident in 
. 
21 to 40 yrs 41 to 60 yrs 61 yrs & 
aboveYes
 
Yes Total 
(100%) (n=53) (100%) (n=75) (100%)
9.1% 0 .0% 2 2.7%
18.2% 6 11.3% 10 13.3%
68.2% 35 66.0% 50 66.7%
4.5% 12 22.6% 13 17.3%
 
Statistical 
inference 
 
 
X2=8.315 
Df=3 
P value 
<0.05 
Significant 
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Chi-square test comparing ECG changes with duration of CKD & eGFR 
DURATION 
ECG Changes 
Statistical 
inference 
No Yes Total 
(n=22) (100%) (n=53) (100%) (n=75) (100%) 
3 to 6months 11 50.0% 37 69.8% 48 64.0% Pvalue >0.05 
Not 
significant 
6 to 12months 7 31.8% 11 20.8% 18 24.0% 
Above 1year 4 18.2% 5 9.4% 9 12.0% 
 
eGFR 
ECG Changes 
Statistical 
inference 
No  Yes  Total  
(n=22) (100%) (n=53) (100%) (n=75) (100%) 
<15 14 63.6% 41 77.4% 55 73.3% P value>0.05 
Not 
Significant 
15-30 8 36.4% 11 20.8% 19 25.3% 
> 30 0 .0% 1 1.9% 1 1.3% 
 
Based on the statistical analysis the changes in ECG were compared with eGFR 
and duration of CKD. Both the analysis only showed an insignificant 
association (p values >0.05). 
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Chi-square test comparing ECG changes with blood urea, serum 
creatinine,  & dyslipidemia 
 
ECG Changes 
Statistical 
inference 
No Yes Total 
(n=22) 
(100
%) 
(n=53) (100%) (n=75) (100%) 
BL.UREA        
60 to 100 5 22.7% 17 32.1% 22 29.3% 
X2=.681 Df=2 
P value >0.05 
Not Significant  
101 to 150 14 63.6% 29 54.7% 43 57.3% 
150 & above 3 13.6% 7 13.2% 10 13.3% 
Sr.Cr        
2 to 4 4 18.2% 8 15.1% 12 16.0% 
X2=1.029 Df=3 
P value >0.05 
Not Significant 
4.1 to 6 8 36.4% 26 49.1% 34 45.3% 
6.1 to 8 4 18.2% 8 15.1% 12 16.0% 
8 & above 6 27.3% 11 20.8% 17 22.7% 
Dyslipidemia         
Absent 17 77.3% 28 52.8% 45 60.0% X
2=3.870 Df=1 
P value <0.05 
Significant Present 5 22.7% 25 47.2% 30 40.0% 
 
The statistical analysis comparing the levels of blood urea with the changes in 
ECG didn’t correlate significantly. The levels of serum creatinine were also 
compared with the ECG changes. The correlation was found to be insignificant 
in our study. The presence of dislipidemia was found to be associated with 
changes in ECG with a significant p value of 0.049. The association of 
dyslipidemia with CAD changes in ECG was not statistically significant.  
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 The changes of ischemia in ECG didn’t correlate significantly with elevated 
total cholesterol and elevated LDL, but ischemic changes correlated 
significantly with elevated levels of serum triglycerides with p value< 0.05. 
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Chi-square test comparing CAD changes 
with levels of TGL 
 
 
 
 
Count ISCH_CHNGE Total  
 
 
P value<0.05 
No Yes 
High  
TGL 
no 57 1 58 
yes 1 16 17  
Total 58 17 75  
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 In our study the lower level of HDL correlated with the presence of coronary 
artery changes in ECG with statistical significance with a p value < 0.05. 
Chi-square test comparing CAD changes 
with levels of HDL 
 
 
  
Count ISCH_CHNGE Total P value<0.05 
No Yes 
lowHDL 
no 57 1 58 
yes 1 16 17  
Total 58 17 75  
100 
 
6. DISCUSSION 
 
CKD is associated with high cardio-vascular mortality and morbidity. As 
the detrimental effects of CKD commences from early stages of CKD.  
Preventive strategies must also start at a very early stage. But the asymptomatic 
nature and the dilemmas in the detection of renal failure in early stages costs the 
valuable time of patients and a proper consultation is hampered .The mean age 
of patients in our study was 50.4±11.5years. Earlier studies also show that the 
prevalence of CKD in 3rd, 4th & 5th decades. In the studies from developed 
countries it has been shown to be beyond the 6th decade of life there is 
prevalence of CKD. 
In this present study comprising of 75 patients of CKD, the ECG change 
of Left ventricular hypertrophy was present in 29.3%.  Previously done studies 
by soman [73] showed LVH in 18% of study group, A.S.Menon’s study[9] 
showed 12% and the study done by Krivoshiev[76] showed 34%, chijoke et al 
[80] study showed LVH in 28%. Our result was comparable to the study done 
by Krivoshiev et al, & chijoke et al. The presence of LVH in our study group 
was limited only to 29.3% even though maximum numbers of patients were 
hypertensive. This brings into account that not only hypertension but also some 
101 
 
other factors are involved in the pathogenesis of LVH. Possible factors include 
the presence of volume overload & anemia. But the emphasize on controlling 
the blood pressure should not be taken lightly as proper control can aid in 
regression of LVH or even prevent its development. The regression in LVH can 
considerably reduce the mortality from cardiac arrhythmias and sudden cardiac 
death. 
  The left atrial enlargement on ECG in our study was seen in 9 out of 75 
patients comprising 12% of the patients. In the study made by A.S.Menon et al 
[9] a similiar proportion of patients i.e. 12% had the same changes. The study 
done by chijoke et al [80] showed 17% of his population with left atrial 
enlargement. 
 The changes pertaining to coronary artery disease was found in 17 out of 
75 patients constituting to around 23%. The previously done studies by 
A.S.Menon [9] showed that 20% of his study population had changes pertaining 
to CAD. In Krivosheiv’s study [76] the percentage of CAD changes was 29% 
and the study made by soman [73] showed that 32% of his study group had 
changes pertaining to CAD. Our study results pertaining to ischemic changes 
can be compared to that of A.S.Menon’s study. The statistical analysis showed 
the significant correlation of ECG changes of ischemia with the elevated serum 
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triglyceride levels and the reduced HDL levels. This emphasizes that statins 
should be used in patients with CKD to prevent the occurrence of CAD.  
 Conduction abnormalities in ECG were found in 13 0f our 75 patients. 
The percentage was 17%. Previous study done by soman et al[73] described a 
similar percentage of people with 15% having conduction disturbances in the 
ECG. The study done by Krivoshiev [76] showed the percentage of conduction 
disturbances to be 11% in his study. A.S.Menon’s study [9] showed 
intraventricular conduction disturbances in 8% of his study population. 
 Hyperkalemic changes in ECG were found to be present in 9 of the total 
75 patients constituting to around 12% of our patients. Arrhythmia was found in 
3 of our patients thus constituting to around 4% of our study population. Study 
made by soman et al [73] showed a similar percentage of people (5%) having 
arrhythmia. 
 Overall ECG changes were found to be present in 53 out of 75 patients 
constituting to around 71%.  29% of the study population (22 patients) had a 
normal ECG. In the study done by Krivoshiev [76] et al 19% of his study 
population had a normal ECG and 81% had abnormal ECG changes.  In the 
study done by chijoke [80] et al 86% of his study population had changes in 
ECG. These overall changes correlated significantly with advancing age and 
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dyslipidaemia. The changes pertaining to coronary artery disease were 
significantly correlated with increased Triglycerides levels and reduced HDL 
levels. 
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7. CONCLUSION 
1. The changes in ECG among CKD patients were frequent and constituted 
to around 71% in our study. 
2. The commonest ECG finding was Left ventricular hypertrophy 
constituting to 29%. 
3. Ischemic changes in ECG were found to be in 23% of our study 
population. 
4. Conduction disturbances in ECG were found to be in 17% of our study 
population. 
5. Left atrial enlargement in ECG was found to be in 12% of our study 
population. 
6. Hyperkalemic changes in ECG were found to be in 12% of our study 
population. 
7. With the advancing age changes in ECG becomes evident in patients with 
CKD and it has been shown with statistical significance. 
8. The presence of Dyslipidemia is significantly associated with the 
presence of changes in ECG. 
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9. The presence of high levels of serum triglycerides and low levels of High 
Density lipoprotein are statistically correlated with the presence of 
changes of coronary artery disease in ECG. 
10. The changes in ECG didn’t correlate with either eGFR, the duration of 
illness, blood urea or serum creatinine levels. 
Cardiovascular diseases propose a major threat to patients with CKD. In the 
context of CKD aim of evaluating CVD is warranted. The changes in ECG of 
patients with CKD can aid in detection of CVD and should be carried out in all 
patients with CKD. 
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ANNEXURE II - PROFORMA  
 
 
 
  
Name : 
Age : 
Sex : 
I.P. No : 
Presenting Complaints 
 
 
Past History 
 
1 Similar complaints    
2 Diabetes Mellitus  
3 Hypertension  
4 Ischemic / Valvular / 
 Pericardial heart disease 
5 Tuberculosis   
 
 
Treatment history 
 
 
Family history 
 
Personal History 
 
Appetite     Normal / Increased / Decreased 
Sleep      Normal / Increased / Decreased 
Bowel     Regular / Irregular 
Bladder Frequency   Normal / Increased / Decreased 
Volume      Normal / Increased / Decreased 
 
 
General Examination 
 
 Built       Well / Moderate / Poor 
 Nutrition     Good / Moderate / Poor 
 Pallor      Present / Absent 
 Nails       clubbing / pallor/ koilonoichyia 
 Cyanosis     Present / Absent 
 Edema      NO /Generalized / Facial/ Pedal 
 Skin      Smooth / Dry/  
 Lymphadenopathy     Present / Absent 
Weight      Kg 
Height      Cm 
Pulse       / Min 
Present   Absent Duration 
   
   
   
   
   
BP       mmHg 
RR       / Min 
Temperature 
       
Systemic examination 
 
Cardiovascular system 
 
 
Respiratory system 
 
Per Abdomen 
 
 
Nervous system 
 
 
Investigations 
 
1. Urine  
Albumin   Present / Absent 
Sugar    Present / Absent 
Microscopy   Casts / Pus cells / EP cells / RBC 
2. Blood  
HB      gm% 
RBS     mg/dl 
FBS     mg/dl 
PPBS     mg/dl   
Blood Urea     mg / dl 
Serum Creatinine   mg / dl 
Electrolytes 
Na+      m Eq / L 
K+      m Eq / L 
 
LIPID PFOFILE 
Total cholesterol  mg/dl 
Triglycerides   mg/dl 
HDL    mg/dl 
LDL    mg/dl 
 
3 .Ultrasound abdomen 
 
 
 
 
 
 
ECG  
Rate 
Rhythm 
P wave 
PR interval 
QRS duration 
QT /QTc 
ST segment 
T wave 
U wave 
Chamber hypertrophy 
Others 
           Inference 
 Echocardiography 
   
  
 
 
 
ANNEXURE III – MASTER CHART 
  
Master chart 
IP.NO SEX AGE  DURATION 
 
UREA creati eGFR HD Na+ K+ HDL TGL LDL T.C. 
41871 m 55 3 months 153 7.3 8 no 128 4.6 44 189 91 184 
42717 M 31 5 months 180 20.2 5 no 135 5.1 43 192 93 192 
42050 m 50 6 months 178 20.2 4 no 124 5.3 46 176 97 179 
41491 f 40 2 years 166 5.7 7 no 136 3.8 42 222 90 167 
42570 f 50 4 months 110 7.7 7 no 131 5.9 51 156 96 167 
42434 f 60 8 months 80 2.5 17 no 135 5.5 50 173 88 163 
42274 f 50 4 months 142 8.3 7 YES 138 5 53 156 78 198 
41767 m 55 4 months 88 3.9 13 no 136 6.2 36 176 132 165 
42683 m 38 3 months 69 2.6 33 no 126 3.5 46 184 90 157 
41758 f 55 6 years 130 8.8 6 no 139 3.9 57 165 92 154 
41955 m 35 1 YR 148 8.7 12 no 144 6 44 178 93 173 
41105 m 70 6 months 62 2.2 23 no 130 5.7 34 212 95 232 
41742 m 62 3 months 84 5 14 no 128 4.5 38 243 142 185 
41738 m 49 3 months 135 9.3 9 YES 117 4.6 45 145 90 184 
41714 m 76 4 months 100 3.4 17 no 132 3.8 43 146 81 195 
41989 m 55 1 YR 92 5 18 no 140 4.2 42 193 83 186 
41309 M 48 4 months 110 6.2 14 YES 134 5.6 46 254 85 167 
41432 m 61 6 months 80 2.8 23 no 128 5.2 45 164 128 256 
41422 m 67 1 YR 79 4 14 no 136 4.8 37 205 79 157 
41555 F 65 3 months 120 5.2 9 YES 132 4.6 50 185 83 185 
41128 F 63 9 months 134 7 7 no 129 5.4 40 235 84 185 
41673 M 55 4 months 130 4.3 17 no 144 5.9 42 138 85 189 
42784 M 52 4 months 98 4.8 17 no 136 7.1 38 260 87 168 
41347 M 23 1 YR 104 6.2 16 YES 126 5.6 46 187 126 187 
41346 m 58 6 months 96 3.8 19 no 135 5.3 43 158 86 160 
41357 M 45 5 months 102 5.7 15 yes 145 4.3 44 147 99 248 
41366 f 52 3 months 126 9 7 no 134 4.3 46 208 75 186 
41386 m 44 4 months 104 3 28 no 138 6 42 186 94 167 
42010 M 52 1 YR 124 4.5 19 YES 129 4.8 50 156 83 184 
41394 M 54 5 months 110 6.2 12 no 136 5.5 38 212 84 169 
42023 F 19 4 months 156 4.6 15 no 126 3.7 56 145 86 156 
41456 M 60 3 YR 84 4.5 13 no 136 6.8 56 182 146 176 
41412 M 60 4 months 162 5.6 10 no 135 4.8 51 164 95 185 
42035 M 54 6 months 140 5.2 13 no 134 5.2 50 165 88 212 
41403 M 65 7 months 112 6.4 9 YES 128 4.9 48 197 79 169 
42047 M 43 3 months 156 9.4 10 no 136 4 40 225 86 154 
41427 F 45 10 months 142 7.5 8 no 143 5.6 54 154 90 178 
42060 M 48 8 months 136 8.6 10 no 140 5.7 48 169 93 187 
41438 F 55 6 months 140 4.6 12 no 132 4.8 46 246 94 198 
42072 M 45 4 months 96 5.2 14 YES 126 5.8 45 154 95 164 
41447 M 53 4 months 118 8.8 8 no 138 4.5 42 176 132 194 
42083 M 24 2 YR 100 5.7 17 no 126 4.4 43 146 140 230 
41461 F 60 3 months 80 4.6 10 no 128 5.4 43 239 97 172 
42095 F 60 4 months 130 7.2 7 no 138 4.3 47 218 93 182 
41475 F 41 6 months 140 9.3 7 YES 140 4.6 52 192 87 184 
42177 F 65 1 YR 176 5.4 8 no 134 6.4 53 183 86 193 
41483 M 18 1 1/2 YR 125 3.9 21 no 128 5.4 43 163 89 190 
42163 M 34 5 months 140 4.2 22 no 134 5.3 45 156 98 187 
41492 M 61 3 months 108 5.8 11 no 140 5 40 159 87 179 
42175 M 48 6 months 114 5.3 14 no 130 5.5 41 164 76 175 
41506 M 52 4 months 126 4 19 no 124 5 42 164 79 188 
42157 M 54 4 months 112 5.9 13 no 128 5.2 36 214 129 191 
41520 F 65 6 months 148 9.2 5 no 126 3.5 54 149 85 177 
42148 F 34 3 months 82 3.4 19 no 130 3.9 56 158 84 194 
41536 M 42 4 months 160 4.9 18 YES 134 6.3 43 164 94 175 
42137 F 63 6 months 138 6.6 8 no 128 5.4 53 176 93 173 
41549 M 66 1 YR 110 5.4 12 no 130 4.6 34 184 97 177 
42123 F 42 4 months 143 4.9 12 no 126 4.7 54 195 88 189 
41560 M 53 3 months 140 6 13 no 135 4 43 176 86 157 
42112 M 48 3 months 134 5.6 14 no 120 4.5 42 173 76 246 
41573 F 42 6 months 138 6 11 no 138 5.5 38 210 83 186 
41892 M 38 4 months 94 9 10 no 126 5.1 44 162 84 182 
41582 F 40 3 months 116 7.1 8 no 129 4.7 56 173 97 192 
41883 M 46 4 months 100 8.2 10 YES 132 4.3 32 248 90 183 
41592 M 53 1 YR 78 4.2 19 no 134 5.2 48 172 79 184 
41871 F 43 6 months 128 4.8 13 no 128 5.7 54 169 86 165 
41599 F 54 4 months 138 8.4 6 no 126 6.9 56 168 147 179 
41848 M 52 2 YR 170 5.3 13 no 134 5.6 48 164 92 172 
41624 M 58 4 months 123 4.2 18 no 136 5.3 53 182 87 178 
41823 M 56 6 months 138 6.8 10 no 138 3.8 44 160 96 195 
41617 M 54 8 months 106 8.9 7 no 120 4.3 46 154 98 241 
41812 F 42 8 months 142 8.3 8 no 140 8 53 148 78 179 
41636 F 48 6 months 98 4.3 13 YES 132 4.8 33 164 76 169 
41809 M 58 5 months 88 4.2 15 no 126 5.5 44 174 88 162 
41642 f 46 7 months 99 4.6 15 no 128 4.2 54 186 136 167 
 
 
ECG and ECHO findings 
IP.NO LVH LAE ISCHEMIA hyperkalemia 
conduction 
abn arrythmia 
echo-
CAD 
echo-
PE 
echo-
LVH 
41871 yes no no no no no no no yes 
42717 no no no no no no no no no 
42050 no no no no no no no no no 
41491 no no yes no no no yes no no 
42570 yes no no yes no no no no yes 
42434 no no no no no no no no no 
42274 no no no no no no no no no 
41767 no no no yes no no no no no 
42683 yes no no no no no no no yes 
41758 no no no no no no no yes no 
41955 no no no yes no no no no no 
41105 no no yes no no no yes no no 
41742 no no yes no yes no yes no no 
41738 no yes no no yes no no yes no 
41714 yes yes no no no no no no yes 
41989 yes no no no no no no no yes 
41309 no no no no yes no no no no 
41432 yes yes no no yes yes no no yes 
41422 yes no yes no no yes yes no yes 
41555 yes yes no no yes no no no yes 
41128 yes no yes no no no yes no yes 
41673 no no no no no no no no no 
42784 yes no yes yes no no yes no yes 
41347 no yes no no no no no no no 
41346 yes no no no yes no no no yes 
41357 no no no no yes no no no no 
41366 no no yes no no no yes no no 
41386 no no no yes no no no no yes 
42010 no no no no no no no no no 
41394 yes yes yes no no no yes no no 
42023 no no no no no no no no yes 
41456 no no no yes no no no no no 
41412 yes no no no no no no no yes 
42035 no no no no no no no no no 
41403 no no no no yes no no no no 
42047 no no yes no no no no no no 
41427 no no no no no no no no no 
42060 no no no no no no no no yes 
41438 no no yes no no no yes no no 
42072 no no no no yes no no no no 
41447 yes no no no no no no no yes 
42083 no no no no no no no no yes 
41461 no no yes no no no yes no no 
42095 yes no yes no no no yes no yes 
41475 no no no no yes no no no no 
42177 no no no yes no no no no no 
41483 no no no no no no no no no 
42163 no no no no yes no no no yes 
41492 no no no no no yes no yes no 
42175 yes no no no no no no no yes 
41506 no no no no no no no no no 
42157 no no yes no no no yes no no 
41520 no yes no no no no no no yes 
42148 no no no no no no no no no 
41536 yes no no yes no no no no yes 
42137 no no no no no no no no yes 
41549 no no yes no no no yes no no 
42123 yes no no no no no no no yes 
41560 no yes no no no no no no no 
42112 no no no no no no no no no 
41573 yes no yes no no no yes no yes 
41892 no no no no yes no no no yes 
41582 no No no no no no no no no 
41883 no No yes no no no yes no no 
41592 no No no no no no no no no 
41871 yes No no no no no no no yes 
41599 no No no no no no no no no 
41848 yes No no no no no no no yes 
41624 yes No no no no no no no yes 
41823 no No no no no no no no no 
41617 no Yes no no no no no no no 
41812 no No no yes no no no no no 
41636 no No yes no no no yes no yes 
41809 no No no no yes no no no yes 
41642 no No no no no no no no no 
 
 
Abbreviations  
UREA- Blood urea levels in mg/dl 
Create- serum creatinine levels in mg/dl 
Na+- serum levels of sodium in meq/l 
K+- serum levels of potassium in meq/l 
T.C.- total cholesterol 
LVH- Left ventricular hypertrophy in ECG 
LAE- Left atrial enlargement in ECG 
ISCHEMIA- Ischemic changes in ECG 
Arrythmia- arrhythmia in ECG 
Conduction abn – conduction disturbances in ecg 
PE- Pericardial effusion 
  
 
 
 
 
 
 
 
ANNEXURE IV-ABBREVIATIONS 
 
  
 
ABBREVIATIONS 
 
CKD - Chronic Kidney Disease  
CVD - Cardiovascular Disease  
CAD- Coronary artery disease 
ESRD- End stage renal disease 
ECG - Electrocardiography  
NKF - National Kidney Foundation  
ECHO - Echocardiography  
GBM- glomerular basement membrane 
JGA- the juxtaglomerular apparatus 
BP-  Blood pressure. 
MDRD- Modification of Diet in Renal Disease 
GFR - Glomerular Filtration Rate  
eGFR - Estimated Glomerular Filtration Rate  
NHANES - National Health and Nutrition Examination Survey  
LVEF - Left Ventricular Ejection Fraction  
LVH - Left Ventricular hypertrophy  
Ca2+- calcium 
Na+- sodium 
H20 – water 
 [Lp(a)]- Lipoprotein-a 
ECF- Extra cellular fluid 
RBC- Red blood cells 
CRP- C reactive protein 
Zn- Zinc 
Se- Selenium 
EBCT- Electron-beam ultrafast computed tomography 
MRI- Magnetic resonance imaging 
LAE- Left atrial enlargement  
HDL - High Density Lipoprotein  
TGL- triglycerides 
VLDL- very low density lipoprotein 
EF - Ejection Fraction  
LDL - Low Density Lipoprotein  
ESRD - End Stage Renal Disease  
RBBB - Right Bundle Branch Block  
LBBB - Left Bundle Branch Block  
MI - Myocardial Infarction  
PTH - Paratharmone 
  
 
 
 
 
ANNEXURE V- CONSENT FORM 
  
    CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR. A. VIMAL RAJ,  post graduate in 
department of General medicine, thanjavur medical college & hospital, 
thanjavur – 613004 and to use my personal clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I 
also give consent for further investigations 
 
 
Place : 
Date :       Signature of participant 
 
 
 
 
 
 
 
 
 
INFORMATION SHEET 
 
 We are conducting a prospective study titled “A Study of 
Electrocardiographic Changes in Patient With Chronic Kidney 
Disease” in the department of General medicine, thanjavur medical 
college & hospital, thanjavur – 613004. 
 
  At the time of announcing the results and suggestions, name and identity 
of the patients will be confidential. 
 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
 The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment.  
 
 
 
 
 
 
Signature of investigator  Signature of participant 
 
Date: 
 
